Search results for " Type 1"

showing 10 items of 430 documents

Contraception in diabetic women: an Italian study

2005

Abstract Over 1 year, a survey on contraception and obstetric history was performed on a cohort of 667 Caucasian fertile diabetic women (446, type 1 and 201, type 2) living in Italy. Results: Of these women, 30.4% used hormonal contraceptives, 12.0% intra-uterine device (IUD), 10.7% declared they used no contraception, 47.0% only utilised barrier and/or natural methods. However, irrespective of their previous contraceptive strategy, 7.2% of all the studied population was surgically sterilized during caesarean section. Hormonal contraception: Of these women, 60.4% was prescribed by a gynaecologist, 11.2% by a diabetologist, 15% by both of them and 13.4% by others. The proportion using oral c…

Adultmedicine.medical_specialtytype 1 diabetesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPopulationdiabetic pregnancycontraception; diabetic pregnancy; type 1 diabetes; type 2 diabetesWhite PeopleCohort StudiesEndocrinologyInternal MedicinemedicineHumansCaesarean sectioneducationGynecologyPregnancyeducation.field_of_studyDiabetic RetinopathyGeographyMarital Statusbusiness.industryObstetricsSmokingGeneral Medicinemedicine.diseaseDiabetes Mellitus Type 1Diabetes Mellitus Type 2ItalycontraceptionHormonal contraceptionFamily planningCohortFemaletype 2 diabetesbusinessDeveloped countryCohort studyDiabetes Research and Clinical Practice
researchProduct

No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.

2013

Context: Women with type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary syndrome (PCOS) than the general population. Objective: The aim of this study was to clarify, in DM1 women with PCOS(PCOS-DM1), the influence of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences with age-matched and body mass index (BMI)-matched women with PCOS without diabetes. Design, Setting, and Patients: We evaluated 103 DM1 women with and without PCOS treated with intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes were compared in a cross-sectional study. Outcome Measurements: Clinical, anthropometric, and metab…

Adultmusculoskeletal diseasesPCOS Type 1 Diabetescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryPopulationContext (language use)BiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationReproductive HistoryMenstrual cyclemedia_commoneducation.field_of_studyType 1 diabetesbusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)nutritional and metabolic diseasesmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsCross-Sectional StudiesDiabetes Mellitus Type 1PhenotypeEndocrinologyCase-Control StudiesFemalebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Patient‐reported outcomes in adults with type 1 diabetes in global real‐world clinical practice: the SAGE study

2021

International audience; Aims: This secondary analysis of the SAGE study aimed to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions.Materials and methods: SAGE was a multinational, cross-sectional, observational study in adults with T1DM. Data were collected at a single visit, analysed according to predefined age groups (26-44, 45-64, and ≥65 years), and reported across different regions. PRO questionnaires were applied to assess hypoglycaemia fear (Hypoglycemia Fear Survey-II [HFS-II]), diabetes-related distress (Problem Areas In Diabetes [PAID]), insulin treatment satisfacti…

Adulttype 1 diabetesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentmedia_common.quotation_subject[SDV]Life Sciences [q-bio]030209 endocrinology & metabolism030204 cardiovascular system & hematologyHypoglycemia03 medical and health sciences0302 clinical medicineEndocrinologyQuality of life (healthcare)Diabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinPatient Reported Outcome Measuresmedia_commonAged[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismGlycated HemoglobinType 1 diabetes[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryInsulin[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle Agedmedicine.disease3. Good health[SDV] Life Sciences [q-bio]DistressCross-Sectional StudiesDiabetes Mellitus Type 1glycaemic controlQuality of LifeObservational studyobservational studyWorrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyClinical psychologyhypoglycaemia
researchProduct

The COVID-19 Pandemic Affects Seasonality, With Increasing Cases of New-Onset Type 1 Diabetes in Children, From the Worldwide SWEET Registry

2022

OBJECTIVE To analyze whether the coronavirus disease 2019 (COVID-19) pandemic increased the number of cases or impacted seasonality of new-onset type 1 diabetes (T1D) in large pediatric diabetes centers globally. RESEARCH DESIGN AND METHODS We analyzed data on 17,280 cases of T1D diagnosed during 2018–2021 from 92 worldwide centers participating in the SWEET registry using hierarchic linear regression models. RESULTS The average number of new-onset T1D cases per center adjusted for the total number of patients treated at the center per year and stratified by age-groups increased from 11.2 (95% CI 10.1–12.2) in 2018 to 21.7 (20.6–22.8) in 2021 for the youngest age-group, <6 years; fr…

Advanced and Specialized NursingGlycated HemoglobinDiabetes Mellitus Type 1AdolescentEndocrinology Diabetes and MetabolismDiabetes Mellitus Type 1/epidemiologyCommunicable Disease ControlInternal MedicineHumansCOVID-19RegistriesChildPandemicsDiabetes Care
researchProduct

Aging modifies receptor expression but not muscular contractile response to angiotensin II in rat jejunum

2022

AbstractThe involvement of renin-angiotensin system in the modulation of gut motility and age-related changes in mRNA expression of angiotensin (Ang II) receptors (ATR) are well accepted. We aimed to characterize, in vitro, the contractile responses induced by Ang II, in jejunum from young (3–6 weeks old) and old rats (≥ 1 year old), to evaluate possible functional differences associated to changes in receptor expression. Mechanical responses to Ang II were examined in vitro as changes in isometric tension. ATR expression was assessed by qRT-PCR. Ang II induced a contractile effect, antagonized by losartan, AT1R antagonist, and increased by PD123319, AT2R antagonist, as well by neural block…

AgingJejunumPhysiologyAngiotensin IIAngiotensin II receptorsIntestinal motilityAnimalsGeneral MedicineReceptor Angiotensin Type 2BiochemistryReceptor Angiotensin Type 1LosartanRats
researchProduct

Agonist-induced formation of FGFR1 homodimers and signaling differ among members of the FGF family

2011

Fibroblast growth factor receptor 1 (FGFR1) is known to be activated by homodimerization in the presence of both the FGF agonist ligand and heparan sulfate glycosaminoglycan. FGFR1 homodimers in turn trigger a variety of downstream signaling cascades via autophosphorylation of tyrosine residues in the cytoplasmic domain of FGFR1. By means of Bioluminescence Energy Resonance Transfer (BRET) as a sign of FGFR1 homodimerization, we evaluated in HEK293T cells the effects of all known FGF agonist ligands on homodimer formation. A significant correlation between BRET(2) signaling and ERK1/2 phosphorylation was observed, leading to a further characterization of the binding and signaling properties…

AgonistMAPK/ERK pathwaymedicine.drug_classBiophysicsSettore BIO/11 - Biologia MolecolareBiologyLigandsFibroblast growth factorSettore BIO/09 - FisiologiaBiochemistrychemistry.chemical_compoundFluorescence Resonance Energy TransfermedicineHumansReceptor Fibroblast Growth Factor Type 1Molecular BiologyMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Fibroblast growth factor receptor 1HEK 293 cellsAutophosphorylationCell BiologyHeparan sulfateFibroblast growth factors FGFR1 Homodimerization BRET MAPKCell biologyFibroblast Growth Factorsstomatognathic diseasesHEK293 CellschemistrySettore BIO/14 - FarmacologiaPhosphorylationHeparitin SulfateProtein MultimerizationBiochemical and Biophysical Research Communications
researchProduct

Enhancement of the FGFR1 signaling in the FGFR1-5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron systems. Relevance for neuroplasticity an…

2015

New findings show existence of FGFR1-5-HT1A heteroreceptor complexes in 5-HT nerve cells of the dorsal and median raphe nuclei of the rat midbrain and hippocampus. Synergistic receptor-receptor interactions in these receptor complexes indicated their enhancing role in hippocampal plasticity. The existence of FGFR1-5-HT1A heteroreceptor complexes also in midbrain raphe 5-HT nerve cells open up the possibility that antidepressant drugs by increasing extracellular 5-HT levels can cause an activation of the FGF-2/FGFR1 mechanism in these nerve cells as well. Therefore, the agonist modulation of the FGFR1-5-HT1A heteroreceptor complexes and their specific role is now determined in rat medullary …

AgonistSerotoninmedicine.medical_specialtymedicine.drug_classCellular differentiationBiophysicsHeteroreceptor complexBiologyHeteroreceptorBiochemistrySettore BIO/09 - FisiologiaCell LineMidbrainDorsal raphe nucleusMesencephalonInternal medicinemedicineAnimalsSerotonin 5-HT1A receptorReceptor Fibroblast Growth Factor Type 1Protein Interaction MapsPhosphorylationExtracellular Signal-Regulated MAP KinasesMolecular BiologyNeurons8-Hydroxy-2-(di-n-propylamino)tetralinNeuronal PlasticityRapheDepressionAnimalExtracellular Signal-Regulated MAP KinaseCell BiologySerotonin 5-HT1 Receptor AgonistsNeuronFibroblast growth factor receptorRatsEndocrinologymedicine.anatomical_structurenervous systemReceptor Serotonin 5-HT1AAutoreceptorRatFibroblast Growth Factor 2Serotonin 5-HT1 Receptor AgonistNeuronDimerizationNeuroscienceDepression; Dimerization; Fibroblast growth factor receptor; Heteroreceptor complex; Neuronal plasticity; Serotonin 5-HT1A receptor; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cell Line; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Mesencephalon; Neurons; Phosphorylation; Rats; Receptor Fibroblast Growth Factor Type 1; Receptor Serotonin 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Neuronal Plasticity; Protein Interaction Maps
researchProduct

Fibroblast Growth Factor Receptor 1– 5-Hydroxytryptamine 1A Heteroreceptor Complexes and Their Enhancement of Hippocampal Plasticity

2011

Background The hippocampus and its 5-hydroxytryptamine transmission plays an important role in depression related to its involvement in limbic circuit plasticity. Methods The analysis was made with bioluminescence resonance energy transfer, co-immunoprecipitation, in situ proximity ligation assay, binding assay, in cell western and the forced swim test. Results Using bioluminescence resonance energy transfer analysis, fibroblast growth factor receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have been demonstrated and their specificity and agonist modulation characterized. Their presence based on co-immunoprecipitation and proximity ligation assay has also been indicated…

Agonistmedicine.medical_specialtyReceptor complexmedicine.drug_classProximity ligation assayBiologyHippocampal formationTransfectionHeteroreceptorSettore BIO/09 - FisiologiaHippocampusRats Sprague-DawleyGrowth factor receptorInternal medicineFluorescence Resonance Energy TransfermedicineAnimalsHumansImmunoprecipitationReceptor Fibroblast Growth Factor Type 1Enzyme InhibitorsRNA Small InterferingCells CulturedBiological PsychiatryNeurons8-Hydroxy-2-(di-n-propylamino)tetralinNeuronal PlasticityDose-Response Relationship DrugFibroblast growth factor receptor 1Computational BiologyAllosteric modulation depression fibroblast growth factor receptor heteroreceptor neuronal plasticity serotonin receptorsRatsSerotonin Receptor AgonistsCell biologyEndocrinologyAnimals NewbornFibroblast growth factor receptorReceptor Serotonin 5-HT1AFibroblast Growth Factor 2PeptidesSignal TransductionBiological Psychiatry
researchProduct

Telmisartan as metabolic modulator: a new perspective in sports doping?

2011

The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-[beta]-D-ribofuranoside (peroxisome proliferator�activated receptor-[delta] [PPAR-[delta]]-5' adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-[delta]-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class �Hormone and metabolic modulators.� This may also be valid for the angotensin II receptor blocker telmisartan. It has recently been shown that telmisartan might induce similar biochemical, biological…

Agonistmedicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorPhysical Therapy Sports Therapy and RehabilitationdopingBenzoatesMiceGene dopingInternal medicinemedicineAnimalsHumansOrthopedics and Sports MedicineTelmisartanMuscle SkeletalDoping in Sportschemistry.chemical_classificationFiber typeTelmisartan; doping; sport.business.industryAMPKGeneral MedicineRatssport.EndocrinologyMitochondrial biogenesischemistryBenzimidazolesTelmisartanbusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.

2020

: ACE2 receptor has a broad expression pattern in the cellular membrane and provides a protective action against the development of cardiovascular diseases. Recently, this enzyme has become of extreme interest during the pandemic infection of COVID-19 (coronavirus disease 2019). This virus invades alveolar epithelium and cardiomyocytes using ACE2 as a transmembrane receptor. ACE2 is a counter-regulatory peptide that degrades Ang II into Ang 1-7, thereby attenuating the biological effects of the AT1 receptor. The binding between the spike protein of COVID-19 and the enzyme is crucial for the virus to enter the target cells, but whether an increase in ACE2 activity could facilitate the infect…

Angiotensin receptorARDSMyocarditisPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPharmacologyPeptidyl-Dipeptidase AVirusSettore MED/11Renin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicinemedicineHumans030212 general & internal medicineReceptorPandemicsDisseminated intravascular coagulationAngiotensin II receptor type 1business.industrySARS-CoV-2COVID-19General MedicineVirus Internalizationmedicine.diseaseCardiovascular DiseasesAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Cardiology and Cardiovascular MedicinebusinessCoronavirus Infectionshormones hormone substitutes and hormone antagonistsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct